Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kyndryl Holdings Inc (KD) vs Dr. Reddy's Laboratories Ltd Common Stock (RDY) Price & Performance

Kyndryl Holdings IncTrade
Dr. Reddy's Laboratories Ltd Common StockTrade

Price performance (Past 24H)

Key statistics

Kyndryl Holdings Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Kyndryl Holdings Inc trades at $11.78 (market cap $2.67B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 4× Kyndryl Holdings Inc's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.

KDRDY
Market Cap
$2.67B$10.78B
Volume
3,966,7872,724,343
Sector
TechnologyHealth
52-Week High
$28.92$15.38
52-Week Low
$10.59$11.38
Typical Hold Time
36 Days0 Days
Enterprise Value
$5.49B$10.68B
Dividend Yield
—0.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kyndryl Holdings Inc

Kyndryl (KD) trades at $12.24, up 3.9% today, with a neutral technical signal and bearish moving averages. The company reported a return to profitability in 2025 with $252M net income after years of losses, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions. The stock faces mixed analyst sentiment with a consensus price target of $14.67, suggesting modest upside potential from current levels.

The outlook for KD hinges on successful execution of its AI and modernization initiatives to drive revenue growth and sustain profitability. Key risks include competitive pressures in IT services and execution challenges in integrating acquisitions. While the valuation appears reasonable with a P/S of 0.19, investors should weigh the company's turnaround progress against ongoing revenue declines and a predominantly neutral analyst rating.

Dr. Reddy's Laboratories Ltd Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KD
100% Buy0% Sell
Avg holding period · 36 Days
RDY
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD →

About Dr. Reddy's Laboratories Ltd Common Stock

Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.

Read more on RDY →